San Carlos, California-based ZAP Surgical Systems has secured $36 million in financing to expand deployment of its robotic radiosurgery platform for treating brain tumors and other neurological conditions.
The financing was led by Catalio Capital Management, with continued participation from Baheal, ZAP's strategic partner in China.
The investment follows a commercial milestone: the company recently shipped its 50th ZAP-X system and reports that nearly 10,000 patients have been treated worldwide using its technology.
ZAP plans to use the new capital to expand manufacturing and deploy additional systems in academic hospitals, community medical centers and specialist practices.
What Is ZAP-X?
ZAP-X is a robotic radiosurgery system designed to deliver precisely targeted radiation to structures inside the brain.
Despite the term radiosurgery, the treatment does not require a conventional surgical incision.
Instead, carefully directed radiation beams target a defined region, allowing physicians to treat certain tumors and neurological conditions without opening the skull.
The system uses a gyroscopic mechanical design that can direct radiation toward the treatment target from multiple angles.
This enables the radiation dose to be concentrated within a selected region while limiting exposure to surrounding tissue.
ZAP-X is also designed to operate without the traditional radiation-shielded treatment vault required by some medical radiation systems.
That could reduce infrastructure requirements for facilities considering installation.
However, vault-free design does not mean a facility can operate the system without radiation safety planning, regulatory approval or appropriate clinical protections.
Who Founded ZAP Surgical?
The company was founded in 2014 by Dr. John R. Adler, a neurosurgeon and professor emeritus at Stanford University.
Adler previously invented the CyberKnife robotic radiosurgery system.
His experience in stereotactic radiosurgery helped shape ZAP-X around the goal of making precise radiation treatment more accessible.
The company has concentrated on brain applications rather than developing a general-purpose radiation therapy platform for the entire body.
That specialization differentiates its product from some of the larger systems used in oncology centers.
Commercial Expansion and Patient Treatments
ZAP reports shipping 50 systems and treating nearly 10,000 patients worldwide.
Its installations span several international markets, including Europe and Asia.
The company is expanding production capacity to support additional deployments.
Its strategic relationship with Baheal has also helped develop its presence in China.
These figures indicate that ZAP-X has moved beyond initial clinical demonstrations into commercial medical use.
However, the company has not publicly disclosed recurring revenue, profitability or average system utilization.
The number of shipped systems should also not be interpreted as the number of systems actively treating patients at any particular time.
Competition in Brain Radiosurgery
ZAP Surgical operates in a market that includes established technologies such as the Gamma Knife and CyberKnife.
These systems deliver highly focused radiation using different mechanical and technical approaches.
ZAP-X's differentiation includes its gyroscopic design, dedicated cranial treatment focus and reduced requirements for specialized radiation vault infrastructure.
Those features could appeal to smaller hospitals and independent treatment centers that cannot justify more complex radiation facilities.
However, purchasing a radiosurgery system involves substantial clinical and financial considerations.
Facilities must assess equipment cost, patient demand, staffing, treatment planning, maintenance and reimbursement.
ZAP's growth will depend on demonstrating that its technology provides clinical and operational benefits sufficient to justify adoption.
Exploring Treatments Beyond Brain Tumors
ZAP is also investigating an experimental approach called radiomodulation.
The concept involves applying precisely targeted low-dose radiation to influence brain activity rather than destroy tumor tissue.
Researchers have begun examining potential applications in treatment-resistant depression and other neurological or psychiatric conditions.
ZAP reported preliminary findings from an early human pilot study involving patients with severe treatment-resistant depression.
The company is planning broader clinical investigations.
However, these applications remain experimental.
Initial findings do not establish that radiomodulation is safe or effective for depression, addiction or other psychiatric disorders.
Larger controlled studies will be necessary to evaluate outcomes, adverse effects and long-term risks.
What Comes Next?
The immediate commercial objective is expanding ZAP-X installations and supporting a larger base of clinical customers.
The longer-term opportunity involves extending the platform beyond established radiosurgery applications into new neurological treatments.
That could significantly expand the market, but it also introduces additional clinical and regulatory uncertainty.
The company's technology must be assessed against established treatment standards, particularly when radiation is being considered for disorders that are not traditionally treated through radiosurgery.
ZAP Surgical has demonstrated commercial adoption in brain radiosurgery. Its next challenge is scaling that installed base while generating credible clinical evidence for any expansion into new therapeutic applications.